Welcome to our dedicated page for Protagonist Ther news (Ticker: PTGX), a resource for investors and traders seeking the latest updates and insights on Protagonist Ther stock.
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company leveraging its proprietary technology platform to discover and develop novel peptide-based drugs. The company's primary focus is on creating first-in-class oral targeted therapies that inhibit biological pathways currently addressed by injectable antibody drugs. This innovative approach aims to treat significant unmet medical needs, particularly in the areas of inflammatory bowel disease (IBD) and other autoimmune diseases.
Protagonist's lead peptide product candidates, PTG-100 and PTG-200, are designed to transform treatment paradigms for conditions such as ulcerative colitis and Crohn's disease. PTG-100, an oral peptide alpha-4-beta-7 integrin antagonist, is in a global Phase 2b clinical trial for moderate-to-severe ulcerative colitis. PTG-200, a first-in-class oral interleukin-23 receptor antagonist, is also progressing through clinical trials.
Another key asset, JNJ-2113 (formerly PN-235), achieved primary and secondary endpoints in the Phase 2b FRONTIER 1 trial for moderate-to-severe plaque psoriasis. This drug is part of an extensive clinical development program, including multiple Phase 3 studies under the ICONIC program. JNJ-2113 is also being evaluated in a Phase 2b ANTHEM-UC study for ulcerative colitis.
Protagonist's pipeline also includes Rusfertide (PTG-300), an injectable hepcidin mimetic currently in Phase 3 development for polycythemia vera. The REVIVE Phase 2 study demonstrated that rusfertide effectively maintains hematocrit control and reduces the need for phlebotomies in patients.
The company has established significant partnerships to further its clinical programs. Notably, Protagonist collaborates with Johnson & Johnson and Takeda Pharmaceuticals to co-develop and co-commercialize its lead candidates, expanding its reach and impact in the biopharmaceutical landscape.
Protagonist continues to drive innovation with its ongoing discovery efforts, aiming to develop additional oral peptides targeting validated biological pathways. With a robust pipeline and strategic collaborations, Protagonist Therapeutics is poised to make substantial contributions to the treatment of autoimmune and hematological diseases.
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) announced that its CEO, Dinesh V. Patel, Ph.D., will participate in a fireside chat at the virtual Piper Sandler 32nd Annual Healthcare Conference from November 30 to December 3, 2020. Registered attendees can view the presentation on the conference site until December 3, and it will also be accessible via the company's Investors section starting November 30. Protagonist focuses on developing peptide-based therapeutics for unmet medical needs, with three clinical-stage assets targeting blood disorders and inflammatory bowel disease.
Protagonist Therapeutics (NASDAQ:PTGX) announced that its President and CEO, Dinesh V. Patel, will join a fireside chat at the Jefferies Virtual 2020 London Healthcare Conference. The event is scheduled for November 17, 2020, at 5:35 p.m. GMT (12:35 p.m. EST). A live and archived webcast will be accessible via the company's website and the provided links.
Protagonist is a clinical-stage biopharmaceutical company focusing on developing peptide-based therapeutics for significant medical needs, currently advancing three clinical-stage assets.
Protagonist Therapeutics (PTGX) reported its third-quarter 2020 financial results, highlighting ongoing Phase 2 clinical studies for its assets PTG-300, PN-943, and PTG-200.
Notably, PTG-300 received orphan designation from the EMA, with full enrollment expected by mid-2021 and a pivotal study slated for the second half of 2021.
In Q3 2020, Protagonist raised $25.3 million through its ATM program and reported revenue of $13.1 million, up from $4.1 million in Q3 2019. Despite a net loss of $7.8 million, losses narrowed from $16.4 million in the same period last year.
Protagonist Therapeutics (NASDAQ: PTGX) announced acceptance of one oral and four poster presentations at the American Society for Hematology (ASH) annual meeting, scheduled for December 5-8, 2020. The data includes results from the ongoing Phase 2 study of PTG-300 for polycythemia vera as of August 2020. The conference will provide a platform to share findings and analysis of patient data, emphasizing the potential of PTG-300, a hepcidin mimetic. CEO Dinesh V. Patel highlighted PTG-300's transformative potential for patients and stressed the goal of achieving regulatory approval efficiently.
Protagonist Therapeutics (Nasdaq:PTGX) announced on October 31, 2020 that it granted an inducement award to Nora Boyer, its newly appointed Vice President of Medical Affairs. The award includes an option to purchase 40,000 shares at an exercise price of $18.95, the closing price on October 30, 2020. Shares will vest over a four-year period, with 25% vesting after one year. This grant complies with NASDAQ Marketplace Rule 5635(c)(4>. Protagonist develops peptide-based therapeutics for unmet medical needs, with three clinical-stage assets including PTG-300 and PTG-200.
Protagonist Therapeutics (NASDAQ: PTGX) announced the progression of two new oral peptide IL-23 receptor antagonists, PN-235 and PN-232, into clinical development as part of its collaboration with Janssen Biotech. These additions complement PTG-200, which is in a Phase 2 study for Crohn's disease. The company aims to leverage these candidates for multiple indications, anticipating the initiation of a Phase 1 study for PN-235 by 2020's fourth quarter. The partnership allows Protagonist to receive milestone payments while Janssen oversees further development.
Protagonist Therapeutics (NASDAQ:PTGX) announced that the European Medicines Agency granted orphan drug designation for PTG-300, aimed at treating polycythemia vera. This synthetic peptide mimetic of hepcidin also received similar designation from the FDA. The company is moving forward with a Phase 2 clinical trial and anticipates launching a pivotal study in mid-2021. Polycythemia vera affects about 100,000 patients in the U.S. and EU, underscoring the need for effective treatments. Orphan drug designation provides advantages for clinical development.
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) will participate in the Jefferies Next Generation IBD Therapeutics Virtual Summit on September 23, 2020, at 8 a.m. EDT. Dinesh V. Patel, Ph.D., the company's President and CEO, will engage in a fireside chat during the event. A live and archived webcast will be available via this link and on the Protagonist website. Protagonist focuses on novel peptide-based therapeutics for unmet medical needs, with three clinical-stage assets including PTG-300 and PTG-200.
Protagonist Therapeutics (Nasdaq:PTGX) announced on September 15, 2020, the issuance of an inducement award to Matthew Gosling, the newly appointed Executive Vice President and General Counsel. This award includes an option to purchase 100,000 shares of common stock at an exercise price of $21.66, matching the stock's closing price on the grant date. The shares will vest over four years, with the first 25% vesting after one year. The award is part of Mr. Gosling's employment terms approved by the company's compensation committee.
Protagonist Therapeutics (NASDAQ: PTGX) has announced that its CEO, Dinesh V. Patel, Ph.D., will engage in a fireside chat at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020, at 11 a.m. EDT. The event will be available via live and archived webcast on the company's investor website. Protagonist Therapeutics focuses on developing novel peptide-based therapeutics, with three clinical-stage assets: PTG-300 for blood disorders, PTG-200 for inflammatory bowel disease, and PN-943 also targeting inflammatory bowel disease.
FAQ
What is the current stock price of Protagonist Ther (PTGX)?
What is the market cap of Protagonist Ther (PTGX)?
What is Protagonist Therapeutics' main focus?
What are PTG-100 and PTG-200?
What is JNJ-2113?
What is rusfertide (PTG-300)?
Who are Protagonist's collaboration partners?
What recent achievements has Protagonist announced?
What is Protagonist's proprietary technology platform?
What are the latest developments in Protagonist's clinical trials?
What is the status of the rusfertide Phase 3 VERIFY trial?
Where can I find more information about Protagonist's drug candidates and clinical studies?
